Morphic Therapeutic is leading the development of a new generation of oral integrin drugs, informed by decades of world-leading expertise and a unique integrin discovery platform. Morphic believes oral drugs targeting the integrin protein family can transform the treatment paradigm for patients suffering from serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, as well as fibrosis and cancer.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
May 17, 2023 at 10:30 AM EDT
Apr 25, 2023 at 8:00 AM EDT
Mar 6, 2023 at 11:10 AM EST
May 12, 2023
May 11, 2023
Morphic Therapeutic Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 05, 2023